|
TANAKA Norina
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Assistant Professor |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Clinical impact of serum soluble SLAMF7 in multiple myeloma. |
| Journal | Formal name：Oncotarget Abbreviation：Oncotarget ISSN code：(1949-2553)1949-2553(Linking) |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 9(78),pp.34784-34793 |
| Author and coauthor | Ishibashi Mariko†, Soeda Saori, Sasaki Makoto, Handa Hiroshi, Imai Yoichi, Tanaka Norina, Tanosaki Sakae, Ito Shigeki, Odajima Takeshi, Sugimori Hiroki, Asayama Toshio, Sunakawa Mika, Kaito Yuta, Kinoshita Ryosuke, Kuribayashi Yasuko, Onodera Asaka, Moriya Keiichi, Tanaka Junji, Tsukune Yutaka, Komatsu Norio, Inokuchi Koiti, Tamura Hideto* |
| Publication date | 2018/10 |
| Summary | The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical significance of serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) and furthermore the impact of sSLMF7 on the antitumor activity of anti-SLAMF7 antibody. Thirty-one percent of MM patients, but not patients with monoclonal gammopathy of undetermined significance and healthy controls, had detectable levels of serum sSLAMF7, which were significantly increased in advanced MM patients. Further, MM in sSLAMF7-postive patients exhibited aggressive clinical characteristics with shorter progression-free survival times in comparison with sSLAMF7-negative patients. In responders to MM therapy, the levels of sSLAMF7 were undetectable or decreased compared with those before treatment. In addition, the anti-SLAMF7 antibody-mediated antibody-dependent cellular cytotoxicity of NK cells against MM cell lines was inhibited by recombinant SLAMF7 protein. Thus, our findings suggest that high concentrations of sSLAMF7, which could transiently suppress the therapeutic effects of elotuzumab, may be a useful indicator of disease progression in MM patients. |
| DOI | 10.18632/oncotarget.26196 |
| PMID | 30410677 |